



Critical Health unveils a Biomarker for Diabetic Retinopathy Progression at the EuRetina Congress in Paris

## Retmarker is a certified Medical Device software

Coimbra, Portugal, 23rd August, 2010 – [Critical Health](#), a provider of innovative decision support software for Ophthalmology, will showcase at the [EuRetina Congress in Paris](#), France (Booth 222B), the Retmarker product suite, a certified Medical Device software (CE 0197). Recently granted in London a [European IT Excellence Award](#), [Retmarker](#) allows physicians to have a more precise source of information, which is not prone to errors related to the complexity in the estimations of lesion areas present in each subfield of the retinography (colour fundus photograph).



Retmarker was developed in close partnership with [AIBILI \(Association for Innovation and Biomedical Research on Light and Image\)](#). Using advanced proprietary algorithms RetmarkerDR monitors the progression of Diabetic Retinopathy, helping ophthalmologists to detect and calculate the formation and disappearance rates of microaneurysms in the retina. Microaneurysms Rates are key indicators of Diabetic Retinopathy progression, a disease that is the highest growing cause of preventable blindness in developed countries.

[RetmarkerDR](#) is backed by leading edge research on Microaneurysm Turnover done by AIBILI (the new and most reliable biomarker of Diabetic Retinopathy progression using non-invasive imaging methods). "According to our research, where we analysed different type 2 diabetic patients with nonproliferative retinopathy, Microaneurysm Turnover was a key factor for the classification in different phenotypes and appears to be a good predictor of progression to Clinically Significant Macular Edema (CSME)," stated Professor Conceição Lobo, lead ophthalmologist and researcher at University Hospital of Coimbra, Portugal.

Ricardo Cunha-Vaz, Critical Health's CEO, states "RetmarkerDR software solution is a breakthrough in predicting Diabetic Retinopathy progression from a Nonproliferative stage to Clinically Significant Macular Edema (CSME), a sight-threatening stage".

To be showcased for the first time at EuRetina is RetmarkerAMD Research, a new software solution under development which enables computer-assisted marking of digital images from patients with Age-related Macular Degeneration (AMD), the main cause of blindness in persons over 50 in developed countries. On the other hand, RetmarkerC enables the detection of changes in the retina over time which can be due to several pathologies.

Also at the 10th EuRetina Congress, Prof. José Cunha-Vaz from Critical Health's partner AIBILI will be presenting a paper, on Main Session 1 "[Research in Retinal Imaging](#)", entitled "Digital Imaging of the Eye Fundus. New approaches". On September 2nd, on Main Session 3 "[Imaging to Monitor Progression](#)", he will present a paper on "Computer-Assisted monitoring of retinal diseases". On the day after, Professor José Cunha-Vaz will take part on Course 4 of the Instructional courses on "[New and future diagnostic tools for retinal diseases](#)", to be followed, in the afternoon, by the presentation of the study "[Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures](#)" at the EVICR.net Retina Session.

## [About Critical Health \(www.critical-health.com\)](http://www.critical-health.com)

Critical Health is a [Critical Software](#) 's healthcare technology division spin-off and a holding of Critical SGPS, committed to the development of groundbreaking technological solutions in the fields of Vision loss and Mobility prevention. Critical Health's first commercial product is Retmarker, a software solution that helps medical doctor's focus their analysis and complementary exams on the most relevant areas of retinographies. The company is also focused on improving patients' quality of care and save caregivers time in Assisted Living facilities. All Critical Health's innovative solutions are developed through partnerships with leading Universities, Hospitals and Scientific Research Institutions.



## For more information please contact:

Rui Melo Biscaia  
Critical Health  
Marcom Manager  
[all-marcom@critical-health.com](mailto:all-marcom@critical-health.com)



© 2010 Critical Health SA. All Rights Reserved.



If you do not wish to receive any further issues of Critical Health, [unsubscribe here](#).

This email is intended solely to those who requested enrolment and can not be considered SPAM. According to international law regulating email, "e-mail can not be considered SPAM when included a form of the receptor to be removed from the list."